Skip to main content

Table 3 The relationship between PD-L1 expression and clinicopathological characteristics in subgroup analysis

From: Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis

Subgroup analysis No. of studies No. of patients Experimental group: positive/total Control group: positive/total OR 95%CI P value Heterogeneity (I2), % Begg’s test (P value) Egger’s test (P value)
Gender 9 3706 Male Female 0.92 0.79–1.07 0.29 0 0.917 0.639
898/1852 1018/1854
The situation of primary tumor 7 2809 T3+T4 T1+T2 1.15 0.68–1.95 0.60 70 0.764 0.115
1018/2176 347/633
The involvement of regional lymph nodes 6 2652 N1+N2 N0 1.32 0.84–2.09 0.23 74 0.060 0.012
558/1225 729/1427
Stage 6 2064 III+IV I+II 1.77 1.41–2.23 P < 0.00001 23 0.452 0.512
594/936 659/1128
Vascular invasion 6 2052 Positive Negative 1.12 0.72–1.75 0.62 63 0.133 0.090
201/564 491/1488
Tumor location 6 3133 Left Right 0.86 0.53–1.40 0.55 82 0.452 0.283
916/1873 711/1260
Microsatellite instability 4 2012 MSI-H MSI-L+MSS 0.95 0.46–1.97 0.89 84 1.000 0.347
223/362 1012/1650
Lymphatic invasion 4 723 Positive Negative 3.49 1.54–7.90 0.003 73 1.000 0.764
122/280 83/443
Tumor differentiation 4 1862 Poor Well to moderate 1.90 0.55–6.63 0.31 88 0.734 0.292
108/156 1057/1706
Mucinous properties 3 1563 Mucinous Other 0.94 0.42–2.10 0.88 56
34/108 573/1455
Grade 3 1562 III I+II 0.66 0.42–1.03 0.07 52
86/239 569/1323